Search results for "B-Lymphocyte Subset"

showing 10 items of 20 documents

Double Negative (IgG+IgD-CD27-) B Cells are Increased in a Cohort of Moderate-Severe Alzheimer’s Disease Patients and Show a Pro-Inflammatory Traffic…

2014

Alzheimer's disease (AD) is a progressive, irreversible, and debilitating disease for which no effective preventive or disease modifying therapies or treatments have so far been detected. The crucial step in AD pathogenesis is the production of amyloid-42 peptide, which causes chronic inflammation. Activated cells in the central nervous system (CNS) produce pro- inflammatory mediators that lead to the recruitment of myeloid or lymphocytic cells. As a consequence, the communication between the CNS and peripheral blood of AD subjects could influence the lymphocyte distribution and/or the expression of phenotypic markers. In the present paper, we show a significant decrease in total CD19 + B l…

MaleReceptors CCR6Receptors CCR7MyeloidLymphocyteB-Lymphocyte SubsetsC-C chemokine receptor type 7InflammationC-C chemokine receptor type 6Immunoglobulin DCD19Cohort StudiesAlzheimer DiseasemedicineHumansB cellAgedAged 80 and overSettore MED/04 - Patologia GeneralebiologyGeneral NeuroscienceGeneral MedicineImmunoglobulin DFlow CytometryTumor Necrosis Factor Receptor Superfamily Member 7Psychiatry and Mental healthClinical Psychologymedicine.anatomical_structurePhenotypeAlzheimer's Disease Inflammation B CellsImmunoglobulin GImmunologybiology.proteinFemaleSettore MED/26 - NeurologiaGeriatrics and Gerontologymedicine.symptomMental Status Schedule
researchProduct

Rituximab in refractory pemphigus vulgaris

2008

Pemphigus vulgaris (PV) is a severe chronic autoimmune blistering disease of skin and mucous membranes. The use of systemic corticosteroids in pemphigus has dramatically reduced its mortality rate, but the long-term use of steroids leads to severe side effects, many of which are serious. For this reason it is often necessary to add immunosuppressive agents to the regimen. However, there are occasional refractory cases in which therapy with conventionally accepted modalities is either not efficacious or not possible on account of side effects. Rituximab is a therapeutic monoclonal antibody targeting CD20, an integral membrane protein highly expressed on the surface of pre-B lymphocytes and a…

Adultmedicine.medical_specialtyAntigens CD19B-Lymphocyte SubsetsDrug ResistanceDermatologyDrug Administration ScheduleAntibodies Monoclonal Murine-DerivedPharmacotherapyRefractoryRituximab pemphigus vulgarisimmune system diseasesHumansImmunologic FactorsMedicineInfusions IntravenousCD20integumentary systembiologybusiness.industryRemission InductionPemphigus vulgarisAntibodies MonoclonalGeneral MedicineAntigens CD20medicine.diseaseDermatologyRegimenPemphigusMonoclonalImmunologybiology.proteinPrednisoneDrug Therapy CombinationFemaleRituximabRituximabbusinessImmunosuppressive AgentsPemphigusmedicine.drugDermatologic Therapy
researchProduct

Treatment of COVID-19 with MSCs: how does it work?

2021

The infusion of coronavirus disease 2019 (COVID-19) patients with mesenchymal stem cells (MSCs) potentially improves clinical symptoms, but the underlying mechanism remains unclear. We conducted a randomized, single-blind, placebo-controlled (29 patients/group) phase II clinical trial to validate previous findings and explore the potential mechanisms. Patients treated with umbilical cord-derived MSCs exhibited a shorter hospital stay (P = 0.0198) and less time required for symptoms remission (P = 0.0194) than those who received placebo. Based on chest images, both severe and critical patients treated with MSCs showed improvement by day 7 (P = 0.0099) and day 21 (P = 0.0084). MSC-treated pat…

Male2019-20 coronavirus outbreakCoronavirus disease 2019 (COVID-19)Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)T-LymphocytesB-Lymphocyte SubsetsAntibodies ViralMesenchymal Stem Cell TransplantationExtracellular TrapsGeneral Biochemistry Genetics and Molecular BiologyArticleImmunomodulationMiceMedicineAnimalsHumansGeneral Environmental ScienceAgedVenous Thrombosisbusiness.industrySARS-CoV-2Mesenchymal stem cellCOVID-19Middle AgedVirologyResearch HighlightMice Inbred C57BLCytoskeletal ProteinsDisease Models AnimalMechanisms of diseaseC-Reactive ProteinWork (electrical)Leukocytes MononuclearMesenchymal stem cellsCytokinesFemaleGeneral Agricultural and Biological SciencesbusinessScience China. Life Sciences
researchProduct

Bone marrow B lymphocytes in multiple myeloma and MGUS: Focus on distribution of naïve cells and memory subsets.

2016

Multiple myeloma (MM) is caused by proliferation of clonal plasma cells (cPCs) in bone marrow (BM), associated with numerical and functional defects in immune subsets. An impairment of B cell compartment is involved in onset/progression of the disease.By flow cytometry, we studied distribution of naïve/transitional (IgD(+)CD27(-)), memory unswitched (IgD(+)CD27(+)), memory switched (IgD(-)CD27(+)) and double negative (DN) (IgD(-)CD27(-)) B lymphocytes in BM of control subjects, and responding and relapsing patients.We observed an increased percentage of IgD(+)CD27(+) B cells in healthy controls vs responding patients (p0.05). Treated non complete responders exhibited an expanded DN compartm…

0301 basic medicineMaleCancer ResearchB-Lymphocyte Subsetschemical and pharmacologic phenomenaBone Marrow CellsImmunoglobulin DMonoclonal Gammopathy of Undetermined SignificanceFlow cytometry03 medical and health sciencesImmune systemstomatognathic systemimmune system diseaseshemic and lymphatic diseasesmedicineHumansB cellMultiple myelomaB-Lymphocyte SubsetsB cellB-Lymphocytesmedicine.diagnostic_testbiologyhemic and immune systemsHematologyImmunoglobulin Dmedicine.diseaseFlow CytometryTumor Necrosis Factor Receptor Superfamily Member 7030104 developmental biologymedicine.anatomical_structureOncologyCase-Control StudiesImmunologybiology.proteinMGUSFemaleBone marrowMultiple MyelomaMonoclonal gammopathy of undetermined significanceLeukemia research
researchProduct

B cells and immunosenescence: a focus on IgG+IgD-CD27- (DN) B cells in aged humans.

2010

Immunosenescence contributes to the decreased ability of the elderly to control infectious diseases, which is also reflected in their generally poor response to new antigens and vaccination. It is known that the T cell branch of the immune system is impaired in the elderly mainly due to expansion of memory/effector cells that renders the immune system less able to respond to new antigens. B lymphocytes are also impaired in the elderly in terms of their response to new antigens. In this paper we review recent work on B cell immunosenescence focusing our attention on memory B cells and a subset of memory B cells (namely IgG(+)IgD(-)CD27(-)) that we have demonstrated is increased in healthy el…

AgingT cellB-Lymphocyte SubsetsBiochemistryImmunoglobulin DImmune systemAntigenmedicineHumansMolecular BiologyB cellCellular SenescenceAgedbiologyImmunosenescenceImmunoglobulin DAcquired immune systemhumanitiesTumor Necrosis Factor Receptor Superfamily Member 7Vaccinationmedicine.anatomical_structureNeurologyImmunoglobulin GImmunologybiology.proteinImmunologic MemoryBiotechnologyAgeing research reviews
researchProduct

Mast cells control the expansion and differentiation of IL-10-competent B cells

2014

Abstract The discovery of B cell subsets with regulatory properties, dependent on IL-10 production, has expanded our view on the mechanisms that control inflammation. Regulatory B cells acquire the ability to produce IL-10 in a stepwise process: first, they become IL-10 competent, a poised state in which B cells are sensitive to trigger signals but do not actually express the Il-10 gene; then, when exposed to appropriate stimuli, they start producing IL-10. Even if the existence of IL-10–competent B cells is now well established, it is not yet known how different immune cell types cross talk with B cells and affect IL-10–competent B cell differentiation and expansion. Mast cells (MCs) contr…

Cell typeRegulatory B cellsCellular differentiationImmunologyCD40 LigandB-Lymphocyte SubsetsRegulatory B cellsB-cellBiologyExosomesLymphocyte ActivationImmunophenotypingMast cellMiceImmunophenotypingImmune systemmedicineImmunology and AllergyAnimalsMast CellsB cell differentiationCD40 AntigensB cellmast cell; IL-10; B-cellMice KnockoutCD40Cell DifferentiationCell biologyInterleukin-10Gastrointestinal TractInterleukin 10medicine.anatomical_structurePhenotypeMast cell; Regulatory B cells; IL-10; B cell differentiationImmunologyIL-10biology.proteinFemaleJournal of immunology (Baltimore, Md.
researchProduct

Anti-tumour necrosis factor-α antibodies and B cell homeostasis in human inflammatory bowel diseases

2017

Background The expression of CD70 on T cells is greatly enhanced by antigen-presenting cell (APC)-associated signals, such as tumour necrosis factor(TNF)-α, which is constitutionally high in patients with inflammatory bowel disease (IBD). Experimentally, the chronic activation of CD27 as a result of the constitutive expression of CD70 leads to the demise of B cells in bone marrow (BM) and the secondary lymphoid organs. The aim of this study was to assess the number and phenotype of circulating B cell in untreated IBD patients and their counterparts treated with biological anti-TNF drugs. Methods The study involved 13 untreated IBD patients, 36 IBD patients treated with biological drugs, and…

Male0301 basic medicineT-LymphocytesImmunophenotypingB cell homeostasisBiological drugs; Inflammatory bowel diseases; Plasmablasts; TNF-αHomeostasisImmunology and AllergyCD20B-LymphocytesbiologyB-LymphocyteAntibodies MonoclonalMiddle AgedFlow Cytometrymedicine.anatomical_structureFemaleTumor necrosis factor alphaImmunotherapyAntibodyPlasmablastsHumanAdultAdolescentBiological drugImmunologyB-Lymphocyte SubsetsPlasmablastCD19ImmunophenotypingYoung Adult03 medical and health sciencesHomeostasimedicineHumansBiological drugsB cellB-Lymphocyte SubsetPharmacologyTumor Necrosis Factor-alphabusiness.industryInflammatory Bowel DiseaseInflammatory Bowel Diseases030104 developmental biologyT-LymphocyteTNF-αImmunologybiology.proteinBone marrowbusinessCD27 LigandInternational Immunopharmacology
researchProduct

Time for a “Plan B” in Peritoneal Metastatic Disease

2019

Abstract Peritoneal involvement in cancer is the harbinger of a particularly unfavorable prognosis. The peritoneal cavity microenvironment is skewed toward immunoregulatory conditions promoted by macrophage populations and innate-like B-1 B cells, which provide immune privilege to malignant cell foci. In this issue of Cancer Research, Haro and colleagues demonstrate that triggering innate IgM-mediated B-1a immune responses via pathogen- or danger-associated molecular pattern recognition exerts antitumor effects on peritoneal metastases by inducing classical complement cascade activation. Exploitation of innate B-1 humoral responses and noncellular immunity is a promising strategy to counter…

0301 basic medicineCancer Research03 medical and health sciencesPeritoneal NeoplasmPeritoneal cavity0302 clinical medicineImmune systemImmune privilegeImmunityTumor MicroenvironmentMedicineMacrophagePeritoneal CavityPeritoneal NeoplasmsB-Lymphocyte SubsetTumor microenvironmentbusiness.industryCancermedicine.diseaseImmunity Innate030104 developmental biologymedicine.anatomical_structureOncology030220 oncology & carcinogenesisCancer researchbusinessHumanCancer Research
researchProduct

Immunophenotypical characterization in Andalusian horse: variations with age and gender.

2010

Abstract Assessment of lymphocyte subsets is an effective method for characterizing disorders such as leukemia, lymphomas, autoimmune and infectious diseases. In order to clinically interpret these parameters, normal reference values should be set, estimating age- and gender-related variations. This research aimed to: (1) characterize lymphocyte subpopulations in Andalusian horse, and (2) evaluate age and gender-related variations of lymphocyte subsets. Jugular blood samples were obtained from 159 animals, 77 males and 82 females, belonging to four age groups—1: 1–2 years (N = 39; 21 males and 18 females), 2: 2–3 years (N = 38; 16 males and 22 females), 3: 3–4 years (N = 41; 19 males and 22…

MaleAgingLymphocyteImmunologyPopulationB-Lymphocyte SubsetsCD4-CD8 RatioPhysiologyBiologyFlow cytometryImmunophenotypingT-Lymphocyte SubsetsmedicineAnimalsHorseseducationeducation.field_of_studySex CharacteristicsGeneral Veterinarymedicine.diagnostic_testAge FactorsHorsemedicine.diseaseFlow CytometryLymphocyte SubsetsLymphomaKiller Cells NaturalLeukemiamedicine.anatomical_structureSpainImmunologybiology.proteinFemaleAntibodyCD8Veterinary immunology and immunopathology
researchProduct

Memory B Cell Subpopulations in the Aged

2006

The literature on immunosenescence has focused mainly on T cell impairment. With the aim of gaining insight into B cell immunosenescence, the authors investigated the serum IgD levels in 24 young and 21 old people and analyzed their relationship with the number of CD19 CD27 memory cells. Serum IgD were quantified by the use of radial immunodiffusion and the lymphocyte population CD19 CD27 was identified by a FACScan flow cytometer. Serum IgD levels were significantly lower (p 0.0001) in old subjects, and the percentage of CD19 CD27 lymphocytes were significantly increased (p 0.01) in old subjects. Finally, a significant negative correlation was found (p 0.01) between serum concentrations of…

AdultMalemedicine.medical_specialtyAgingLymphocyteT cellPopulationAntigens CD19B-Lymphocyte Subsetschemical and pharmacologic phenomenaimmunosenescence memory B cells IgD CD27Immunoglobulin DCD19immune system diseaseshemic and lymphatic diseasesInternal medicinemedicineHumanseducationMemory B cellB cellAgedAged 80 and overSettore MED/04 - Patologia Generaleeducation.field_of_studybiologyhemic and immune systemsImmunosenescenceImmunoglobulin DTumor Necrosis Factor Receptor Superfamily Member 7Endocrinologymedicine.anatomical_structureImmunologybiology.proteinFemaleGeriatrics and GerontologyImmunologic Memory
researchProduct